Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co. - Appili Therapeutics
Summary
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESHALIFAX, Nova Scotia April 26, 2024 Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000 (the Bridge Loan) from Bloom Burton & Co. Inc. (the Lender). Additionally, the Company is exempt from the minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Companys market capitalization.This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein. By systematically identifying urgent infections with unmet needs, Appilis goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. Wherever possible, words such as may , would, could , should, will, anticipate, believe, plan, expect, intend, estimate, potential for and similar expressions have been used to identify these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.